ImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 For Immediate Release

Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022

PORTLAND, Maine - April 11, 2022 - ImmuCell

Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops,

manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle,

today announced preliminary, unaudited sales results for the first quarter ended March 31, 2022.

Unaudited Total Sales Results:

"Sales during the first quarter ended March 31, 2022 increased

by 46% to $6.0 million compared to the same period of the prior year, which is exciting for us," commented Michael F. Brigham, President

and CEO of ImmuCell. "This favorable comparison does reflect tighter supply constraints during the first quarter of 2021 before

the first level of investments to increase our production capacity had been completed."

strategic investments we have been making to incrementally expand our First Defense

manufacturing capacity from approximately $16.5 million to approximately $35 million are beginning to pay off," added Mr. Brigham.

"Our 2022 first quarter annualized manufacturing output reached $23.8 million, exceeding the current level of $23 million of annual

production capacity that we targeted for the end of 2021."

The Company has initiated an additional investment to further increase

its annual First Defense manufacturing capacity to approximately $35 million by the end of 2022. The capacity estimates

above are subject to biological yield variance, product format mix, selling price and other factors.

"Our work to achieve regulatory approval to commercialize Re-Tain

continues," Mr. Brigham concluded. "We expect a response from the FDA during the third quarter to our submission of the final

Technical Section required to complete our New Animal Drug Application, and we are preparing our responses to the findings from a recent

pre-approval inspection by the FDA."

Since the first quarter of 2020, the Company has been providing a preliminary look at its top line results soon after the close

of the quarter. The Company expects to provide this prompt, preliminary report on product sales until further notice going forward. The

Company will host a conference call on Friday, May 13, 2022 at 9:00 AM ET to discuss the full financial results for the quarter ended

March 31, 2022. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international)

at 9:00 AM ET. A teleconference replay of the call will be available for seven days at (877) 344-7529 (toll free) or (412) 317-0088 (international),

utilizing confirmation #6767746. Investors are encouraged to review the Company's updated Corporate Presentation slide deck that

provides an overview of the Company's business and is available under the "Investors" tab of the Company's website

at www.immucell.com, or by request to the Company.

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health

and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense , providing Immediate

Immunity to newborn dairy and beef calves, and is in the late stages of developing Re-Tain , a novel

treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.

Press releases and other information about the Company are available at: http://www.immucell.com.

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor

This Press Release contains "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements

include, but are not limited to, any statements relating to: our plans and strategies for our business; projections of future financial

or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals; factors that may affect

the dairy and beef industries and future demand for our products; the extent, nature and duration of the COVID-19 pandemic and its consequences,

and their direct and indirect impacts on our production activities, operating results and financial condition and on the customers and

markets that we serve; the impact of Russia's unprovoked military invasion of Ukraine and attack on its people on the world economy

including inflation and the price and availability of grain and oil; the impact of the global supply-chain disruptions on our ability

to obtain, in a timely and cost-effective fashion, all the supplies and components we need to produce our products; the impact of inflation

and rising interest rates on our operating expenses and financial results; the scope and timing of ongoing and future product development

work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical

mastitis and producers' level of interest in treating subclinical mastitis given the current economic and market conditions; the

expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated by current

products and products still in development; our ability to increase production output and reduce costs of goods sold per unit; the future

adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for

our products on a timely basis; the impacts of backlogs on customer relationships; the anticipated costs of (or time to complete) planned

expansions of our manufacturing facilities and the adequacy of our funds available for these projects; the continuing availability to

us on reasonable terms of third-party providers of critical products or services; the robustness of our manufacturing processes and related

technical issues; estimates about our production capacity, efficiency and yield, which are highly subject to biological variability and

the product format mix of our sales; the future adequacy of our working capital and the availability and cost of third-party financing;

future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants;

costs associated with sustaining compliance with current Good Manufacturing Practice (cGMP) regulations in our current operations and

attaining such compliance for our facilities to produce the Nisin Drug Substance and Drug Product; our effectiveness in competing against

competitors within both our existing and our anticipated product markets; the cost-effectiveness of additional sales and marketing expenditures

and resources; anticipated changes in our manufacturing capabilities and efficiencies; the value of our net deferred tax assets; projections

about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical

facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates",

"aims", "intends", "would", "could", "should", "will", "plans",

"believes", "estimates", "targets", "projects", "forecasts", "seeks"

and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we

anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to:

difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the First

Defense product line and Re-Tain ), competition within our anticipated product markets, customer

acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including

the consequences of backlogs or excess inventory buildup), uncertainty associated with the timing and volume of customer orders as we

come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer relationships, our reliance

upon third parties for financial support, products and services, our small size and dependence on key personnel, changes in laws and regulations,

decision making and delays by regulatory authorities, a recurrence of inflation and its impact on our customers' order patterns,

currency values and fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission

(SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements

involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors,

including the risk factors summarized above.